Skip to main content
Livermore
Livermore
ZHEN

Vestal Point Capital, LP

SEC CIK
0001974915
Latest filing
Aug 14, 2026

The latest 13F from Vestal Point Capital, LP covers Q2 2026 (filed Aug 14, 2026): 68 long positions worth $4.28B. The top 10 holdings make up 50.3% of the portfolio, and the largest is Biomarin Pharmaceutical Inc (BMRN) at 8.1%. Livermore has 11 filings on Form 13F from this institution, going back to Q4 2023.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
9
Est. +$225.0M
Added
31
Est. +$1.27B
Reduced
22
Est. −$686.9M
Sold out
31
Est. −$761.0M

Top 5 holdings

Share of this quarter's portfolio value

  1. BMRNBiomarin Pharmaceutical Inc
    8.1%$344.8MHistory
  2. NBIXNeurocrine Biosciences Inc
    7.4%$316.8MHistory
  3. ABVXAbivax S.A.
    7.3%$313.1MHistory
  4. UTHRUnited Therapeutics Corp
    5.5%$235.7MHistory
  5. ELVNEnliven Therapeutics, Inc.
    4.7%$203.0MHistory

Share of portfolio

Top 5 holdings and the other 63 positions, by share of portfolio value

  1. BMRN8.1%
  2. NBIX7.4%
  3. ABVX7.3%
  4. UTHR5.5%
  5. ELVN4.7%
  6. Other 63 positions67.0%

Biggest buys

New and added positions, by estimated amount bought

  1. UTHRUnited Therapeutics Corp
    +$195.1MAddedHistory
  2. BMRNBiomarin Pharmaceutical Inc
    +$140.2MAddedHistory
  3. ABTAbbott Laboratories
    +$127.0MNewHistory
  4. ABVXAbivax S.A.
    +$113.2MAddedHistory
  5. NBIXNeurocrine Biosciences Inc
    +$106.2MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. UTHRUnited Therapeutics Corp
    +4.26 pp1.2% → 5.5%History
  2. ABTAbbott Laboratories
    +2.97 pp0.0% → 3.0%History
  3. NBIXNeurocrine Biosciences Inc
    +2.80 pp4.6% → 7.4%History
  4. ABVXAbivax S.A.
    +2.65 pp4.7% → 7.3%History
  5. BMRNBiomarin Pharmaceutical Inc
    +2.41 pp5.6% → 8.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. RVMDRevolution Medicines, Inc.
    −$360.5MReducedHistory
  2. APGEApogee Therapeutics, Inc.
    −$92.6MSold outHistory
  3. RGENRepligen Corp
    −$71.6MReducedHistory
  4. SRRKScholar Rock Holding Corp
    −$65.1MSold outHistory
  5. ARWRArrowhead Pharmaceuticals, Inc.
    −$57.1MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. RVMDRevolution Medicines, Inc.
    −4.49 pp6.5% → 2.0%History
  2. APGEApogee Therapeutics, Inc.
    −2.59 pp2.6% → 0.0%History
  3. SRRKScholar Rock Holding Corp
    −1.82 pp1.8% → 0.0%History
  4. RGENRepligen Corp
    −1.77 pp3.0% → 1.3%History
  5. VERAVera Therapeutics, Inc.
    −1.54 pp1.5% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$4.28B
+$702.6M (+19.6%) vs. prior quarter
Positions
68
−22 vs. prior quarter
Top 10 concentration
50.3%
Top 10 as share of value
Turnover
36.9%
Q2 2026, one quarter
Average holding period
4.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2023), so positions held before then are understated.

13F filings by quarter

11 quarters, going back to Q4 2023. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $4.28B (Q2 2026)

Q4 2023: $944.0MQ1 2024: $1.21BQ2 2024: $1.34BQ3 2024: $1.27BQ4 2024: $1.69BQ1 2025: $1.40BQ2 2025: $1.90BQ3 2025: $2.20BQ4 2025: $2.73BQ1 2026: $3.58BQ2 2026: $4.28B
Q4 2023Q2 2026
13F filings of Vestal Point Capital, LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202668$4.28BBMRNNBIXABVXvs. Q1 2026SEC
Q1 2026May 15, 202690$3.58BRVMDBMRNABVXvs. Q4 2025SEC
Q4 2025Feb 17, 202675$2.73BABVXACLXTERNvs. Q3 2025SEC
Q3 2025Nov 14, 202580$2.20BASNDACLXNUVLvs. Q2 2025SEC
Q2 2025Aug 14, 202572$1.90BACLXJAZZCYTKvs. Q1 2025SEC
Q1 2025May 15, 202563$1.40BACLXCYTKINSMvs. Q4 2024SEC
Q4 2024Feb 14, 202573$1.69BJAZZCYTKMRKvs. Q3 2024SEC
Q3 2024Nov 14, 202467$1.27BINSMJAZZCYTKvs. Q2 2024SEC
Q2 2024Aug 14, 202460$1.34BJAZZCYTKASNDvs. Q1 2024SEC
Q1 2024May 14, 202458$1.21BCYTKJAZZNBIXvs. Q4 2023SEC
Q4 2023Feb 13, 202448$944.0MNBIXJAZZASND–SEC

13D and 13G filings

Companies where Vestal Point Capital, LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

12 companies, largest stake first.

Companies where Vestal Point Capital, LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
APREAprea Therapeutics, Inc.13G9.90%22.7M sharesNewMay 15, 20261 filingMay 15, 2026SEC
TENXTenax Therapeutics, Inc.13G9.90%2.47M sharesNewNov 14, 20251 filingNov 14, 2025SEC
BCAXBicara Therapeutics Inc.13G/A8.30%5.42M shares+1.80 ppfrom 6.50%May 15, 20254 filingsMay 15, 2026SEC
IBIOiBio, Inc.13G/A7.90%4.03M shares−2.00 ppfrom 9.90%Nov 14, 20252 filingsAug 14, 2026SEC
NRIXNurix Therapeutics, Inc.13G/A7.80%8.05M shares+1.50 ppfrom 6.30%May 15, 20262 filingsAug 14, 2026SEC
LXEOLexeo Therapeutics, Inc.13G/A7.50%4.12M shares+1.50 ppfrom 6.00%Aug 14, 20252 filingsNov 14, 2025SEC
TSHATaysha Gene Therapies, Inc.13G/A6.30%18.0M shares+1.30 ppfrom 5.00%Feb 17, 20262 filingsMay 15, 2026SEC
MYGNMyriad Genetics Inc13G6.10%5.74M sharesNewAug 14, 20261 filingAug 14, 2026SEC
GLUEMonte Rosa Therapeutics, Inc.13G5.40%4.60M sharesNewAug 14, 20261 filingAug 14, 2026SEC
ELVNEnliven Therapeutics, Inc.13G/A5.40%3.25M shares−1.10 ppfrom 6.50%Feb 17, 20262 filingsMay 15, 2026SEC
CBIOCrescent Biopharma, Inc.13G5.40%1.50M sharesNewFeb 17, 20261 filingFeb 17, 2026SEC
DRUGBright Minds Biosciences Inc.13G5.00%492.3K sharesNewMay 15, 20261 filingMay 15, 2026SEC

Latest filings

66 filings on file made by Vestal Point Capital, LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Vestal Point Capital, LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
GLUEMonte Rosa Therapeutics, Inc.Aug 14, 20264:10 PM ET13G5.40%4.60M sharesNewJun 30, 2026SEC
MYGNMyriad Genetics IncAug 14, 20264:09 PM ET13G6.10%5.74M sharesNewJun 30, 2026SEC
SLDBSolid Biosciences Inc.Aug 14, 20264:08 PM ET13G/A4.80%4.83M shares−2.70 ppfrom 7.50%Below 5%Jun 30, 2026SEC
IMCRImmunocore Holdings plcAug 14, 20264:08 PM ET13G/A3.50%1.80M shares−2.00 ppfrom 5.50%Below 5%Jun 30, 2026SEC
NRIXNurix Therapeutics, Inc.Aug 14, 20264:07 PM ET13G/A7.80%8.05M shares+1.50 ppfrom 6.30%Jun 30, 2026SEC
ANROAlto Neuroscience, Inc.Aug 14, 20264:06 PM ET13G/A2.20%785.0K shares−4.30 ppfrom 6.50%Below 5%Jun 30, 2026SEC
IBIOiBio, Inc.Aug 14, 20264:05 PM ET13G/A7.90%4.03M shares−2.00 ppfrom 9.90%Jun 30, 2026SEC
PASGPassage BIO, Inc.Aug 14, 20264:05 PM ET13G/A0.00%0 shares–Below 5%Jun 30, 2026SEC
TSHATaysha Gene Therapies, Inc.May 15, 20265:09 PM ET13G/A6.30%18.0M shares+1.30 ppfrom 5.00%Mar 31, 2026SEC
BCAXBicara Therapeutics Inc.May 15, 20265:06 PM ET13G/A8.30%5.42M shares+1.80 ppfrom 6.50%Mar 31, 2026SEC
ELVNEnliven Therapeutics, Inc.May 15, 20265:05 PM ET13G/A5.40%3.25M shares−1.10 ppfrom 6.50%Mar 31, 2026SEC
ANROAlto Neuroscience, Inc.May 15, 20265:05 PM ET13G/A6.50%2.06M shares−1.50 ppfrom 8.00%Mar 31, 2026SEC
IMTXImmatics N.V.May 15, 20265:03 PM ET13G/A4.60%6.17M shares−0.70 ppfrom 5.30%Below 5%Mar 31, 2026SEC
ACLXArcellx, Inc.May 15, 20265:03 PM ET13G/A0.00%0 shares−5.10 ppfrom 5.10%Below 5%Mar 31, 2026SEC
DAWNDay One Biopharmaceuticals, Inc.May 15, 20265:02 PM ET13G/A0.00%0 shares−5.10 ppfrom 5.10%Below 5%Mar 31, 2026SEC
DRUGBright Minds Biosciences Inc.May 15, 20265:02 PM ET13G5.00%492.3K sharesNewMar 31, 2026SEC
NRIXNurix Therapeutics, Inc.May 15, 20265:01 PM ET13G6.30%6.50M sharesNewMar 31, 2026SEC
APREAprea Therapeutics, Inc.May 15, 20265:00 PM ET13G9.90%22.7M sharesNewMar 31, 2026SEC
IMCRImmunocore Holdings plcMay 15, 20265:00 PM ET13G5.50%2.77M sharesNewMar 31, 2026SEC
BCAXBicara Therapeutics Inc.Feb 17, 20264:10 PM ET13G/A6.50%3.58M shares−2.70 ppfrom 9.20%Dec 31, 2025SEC